MitchellS.SteinerMD

Surgical Oncology

Chairman, CEO, and President of Veru, Inc. (NASDAQ:VERU) 2014-present CEO, Vice Chairman of GTx (NASDAQ:GTXI) 1997-2014 Chairman and Professor, Urology, University of Tennessee, Memphis, College of Medicine

Join to view full profile

Dr. Steiner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Steiner's full profile

Already have an account?

Office
48 NW 25th Street
Suite 102
Miami, FL 33127
Phone+1 901-581-5872

Education & Training

Johns Hopkins UniversityResidency, Urology, 1988 - 1992
Johns Hopkins UniversityResidency, Surgery, 1986 - 1988
University of Tennessee Health Science Center College of MedicineClass of 1986

Certifications & Licensure

TN State Medical License 1992 - 2026
MD State Medical License 1989 - 1993

Awards, Honors, & Recognition

Fellow (FACS) American College of Surgeons

Clinical Trials

Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy Start of enrollment: 2003 Oct 01
Completed
Phase 3
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer Start of enrollment: 2011 Mar 01
Withdrawn
Phase 3
Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer Start of enrollment: 2011 Jun 01
Terminated
Phase 2
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum Start of enrollment: 2011 Jul 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

16 citations
A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Re...
Mark C Markowski, Ronald Tutrone, Christopher Pieczonka, K Gary Barnette, Robert H Getzenberg
Clinical Cancer Research. 2022-07-01
4 citations
The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.
Michael A. Maccini, Nicholas Westfall, Adrie van Bokhoven, Marshall Scott Lucia, Wendy Poage
The Prostate. 2018-02-19
15 citations
Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer
Evan Y. Yu, Robert H. Getzenberg, Christopher C. Coss, Marc M. Gittelman, Thomas E. Keane
European Urology. 2015-02-01

Press Mentions

Veru to Present at the Jefferies Healthcare ConferenceMay 24th, 2023
Veru Reports Fiscal 2023 Second Quarter Financial ResultsMay 11th, 2023
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDSMay 4th, 2023
Join now to see all